The increasing prevalence of Alzheimer’s disease and the lack of successful drugs in clinical trials result in a significant healthcare burden. This project aims at prospectively evaluating …
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, or purchase a new subscription.
If you are a digital subscriber with an active, online-only subscription then you already have an account here. Just reset your password if you've not yet logged in to your account on this new site.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
The increasing prevalence of Alzheimer’s disease and the lack of successful drugs in clinical trials result in a significant healthcare burden. This project aims at prospectively evaluating chloride channel-targeted therapy for attenuating maladaptive immune response in Alzheimer’s disease.
This study may lay the foundation for chloride physiology and prospective validation of chloride channel-targeted therapy against Alzheimer’s disease and related neurological disorders.
"This project is about testing a new treatment that targets specific channels in cells to see if it can help reduce the harmful sustained immune response in Alzheimer's disease," Leung explained.
Leung joined Clarkson University as an assistant professor in the Department of Chemistry & Biomolecular Science in 2021. His research interests lie in developing subcellular imaging tools for cell physiology investigation. He was awarded the NIH 2022 Maximizing Investigators’ Research Award. The K. Leung research group has secured around $2.2 million in federal research grants since its inception.